Literature DB >> 28904072

Validation of a Novel Assay to Distinguish Bacterial and Viral Infections.

Isaac Srugo1,2, Adi Klein3, Michal Stein4, Orit Golan-Shany2, Nogah Kerem5,2, Irina Chistyakov5,2, Jacob Genizi2, Oded Glazer2, Liat Yaniv2, Alina German2, Dan Miron6, Yael Shachor-Meyouhas7, Ellen Bamberger5,2,8, Kfir Oved8, Tanya M Gottlieb8, Roy Navon8, Meital Paz8, Liat Etshtein8, Olga Boico8, Gali Kronenfeld8, Eran Eden8, Robert Cohen9, Helène Chappuy10, François Angoulvant11, Laurence Lacroix12, Alain Gervaix12.   

Abstract

BACKGROUND: Reliably distinguishing bacterial from viral infections is often challenging, leading to antibiotic misuse. A novel assay that integrates measurements of blood-borne host-proteins (tumor necrosis factor-related apoptosis-inducing ligand, interferon γ-induced protein-10, and C-reactive protein [CRP]) was developed to assist in differentiation between bacterial and viral disease.
METHODS: We performed double-blind, multicenter assay evaluation using serum remnants collected at 5 pediatric emergency departments and 2 wards from children ≥3 months to ≤18 years without (n = 68) and with (n = 529) suspicion of acute infection. Infectious cohort inclusion criteria were fever ≥38°C and symptom duration ≤7 days. The reference standard diagnosis was based on predetermined criteria plus adjudication by experts blinded to assay results. Assay performers were blinded to the reference standard. Assay cutoffs were predefined.
RESULTS: Of 529 potentially eligible patients with suspected acute infection, 100 did not fulfill infectious inclusion criteria and 68 had insufficient serum. The resulting cohort included 361 patients, with 239 viral, 68 bacterial, and 54 indeterminate reference standard diagnoses. The assay distinguished between bacterial and viral patients with 93.8% sensitivity (95% confidence interval: 87.8%-99.8%) and 89.8% specificity (85.6%-94.0%); 11.7% had an equivocal assay outcome. The assay outperformed CRP (cutoff 40 mg/L; sensitivity 88.2% [80.4%-96.1%], specificity 73.2% [67.6%-78.9%]) and procalcitonin testing (cutoff 0.5 ng/mL; sensitivity 63.1% [51.0%-75.1%], specificity 82.3% [77.1%-87.5%]).
CONCLUSIONS: Double-blinded evaluation confirmed high assay performance in febrile children. Assay was significantly more accurate than CRP, procalcitonin, and routine laboratory parameters. Additional studies are warranted to support its potential to improve antimicrobial treatment decisions.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28904072     DOI: 10.1542/peds.2016-3453

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  20 in total

1.  RNA-Seq Data-Mining Allows the Discovery of Two Long Non-Coding RNA Biomarkers of Viral Infection in Humans.

Authors:  Ruth Barral-Arca; Alberto Gómez-Carballa; Miriam Cebey-López; María José Currás-Tuala; Sara Pischedda; Sandra Viz-Lasheras; Xabier Bello; Federico Martinón-Torres; Antonio Salas
Journal:  Int J Mol Sci       Date:  2020-04-15       Impact factor: 5.923

2.  C-reactive protein point of care testing in the management of acute respiratory infections in the Vietnamese primary healthcare setting - a cost benefit analysis.

Authors:  Yoel Lubell; Nga T T Do; Kinh V Nguyen; Ngan T D Ta; Ninh T H Tran; Hung M Than; Long B Hoang; Poojan Shrestha; Rogier H van Doorn; Behzad Nadjm; Heiman F L Wertheim
Journal:  Antimicrob Resist Infect Control       Date:  2018-10-04       Impact factor: 4.887

3.  A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study.

Authors:  Liat Ashkenazi-Hoffnung; Kfir Oved; Roy Navon; Tom Friedman; Olga Boico; Meital Paz; Gali Kronenfeld; Liat Etshtein; Asi Cohen; Tanya M Gottlieb; Eran Eden; Irina Chistyakov; Isaac Srugo; Adi Klein; Shai Ashkenazi; Oded Scheuerman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-26       Impact factor: 3.267

Review 4.  Biomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management.

Authors:  Elena N Savvateeva; Alla Yu Rubina; Dmitry A Gryadunov
Journal:  Biomed Res Int       Date:  2019-04-30       Impact factor: 3.411

5.  Update of a clinical prediction model for serious bacterial infections in preschool children by adding a host-protein-based assay: a diagnostic study.

Authors:  Chantal van Houten; Josephine Sophia van de Maat; Christiana Naaktgeboren; Louis Bont; R Oostenbrink
Journal:  BMJ Paediatr Open       Date:  2019-09-20

6.  Coinfections in Hospitalized Children With Community-Acquired Pneumonia: What Does This Mean for the Clinician?

Authors:  Sheldon L Kaplan
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

Review 7.  Community-acquired pneumonia among children: the latest evidence for an updated management.

Authors:  Cristiana M Nascimento-Carvalho
Journal:  J Pediatr (Rio J)       Date:  2019-09-10       Impact factor: 2.197

Review 8.  The integrated management of childhood illness (IMCI) and its potential to reduce the misuse of antibiotics.

Authors:  Susanne Carai; Aigul Kuttumuratova; Larisa Boderscova; Henrik Khachatryan; Ivan Lejnev; Kubanychbek Monolbaev; Sami Uka; Martin W Weber
Journal:  J Glob Health       Date:  2021-05-22       Impact factor: 4.413

Review 9.  Future Biomarkers for Infection and Inflammation in Febrile Children.

Authors:  Judith Zandstra; Ilse Jongerius; Taco W Kuijpers
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

10.  Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection.

Authors:  Faisal Kamal; Sacheen Kumar; Michael R Edwards; Kirill Veselkov; Ilaria Belluomo; Tatiana Kebadze; Andrea Romano; Maria-Belen Trujillo-Torralbo; Tasnim Shahridan Faiez; Ross Walton; Andrew I Ritchie; Dexter J Wiseman; Ivan Laponogov; Gavin Donaldson; Jadwiga A Wedzicha; Sebastian L Johnston; Aran Singanayagam; George B Hanna
Journal:  Am J Respir Crit Care Med       Date:  2021-11-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.